or Try an Advanced Search...

    Technical Analysis for INAB - IN8bio, Inc.

    Grade Last Price % Change Price Change
    F 0.29 2.21% 0.01
    INAB closed up 2.21 percent on Friday, November 1, 2024, on 19 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical INAB trend table...
    Date Alert Name Type % Chg
    20 DMA Support Bullish 0.00%
    Stochastic Buy Signal Bullish 0.00%
    Spinning Top Other 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Crossed Above 20 DMA Bullish 2.21%
    Outside Day Range Expansion 2.21%
    Wide Bands Range Expansion 2.21%
    Oversold Stochastic Weakness 2.21%
    Fell Below 20 DMA Bearish 6.03%
    Older End-of-Day Signals for INAB ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 22 hours ago
    Up 5% about 22 hours ago
    Up 3% about 22 hours ago
    60 Minute Opening Range Breakout about 22 hours ago
    Up 2% about 22 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    INAB Chart by TradingView
    Basic chart:

    Profile

    IN8bio, Inc. Description

    IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Treatment Of Cancer Stem Cell Transplantation Solid Tumor Cancers Acute Leukemia Regenerative Medicine Advanced Therapy

    Is INAB a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 3 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 9 Why Saratoga Investment Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
    Oct 2 INAB: Restructuring Narrows Focus to AML
    Oct 1 IN8bio dips 9%, prices $12.4M private placement
    Oct 1 IN8bio Announces Pricing of $12.4 Million Private Placement
    Sep 5 IN8bio cuts staff and pipeline to focus on AML cell therapy
    Sep 4 IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia
    Aug 29 IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    Aug 14 INAB: AML & GBM Clinical Update
    Aug 12 IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100
    Aug 9 IN8bio GAAP EPS of -$0.19
    See more INAB news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.47
    52 Week Low 0.217
    Average Volume 1,097,643
    200-Day Moving Average 0.86
    50-Day Moving Average 0.32
    20-Day Moving Average 0.28
    10-Day Moving Average 0.32
    Average True Range 0.04
    RSI (14) 47.37
    ADX 45.61
    +DI 33.08
    -DI 16.76
    Chandelier Exit (Long, 3 ATRs) 0.43
    Chandelier Exit (Short, 3 ATRs) 0.35
    Upper Bollinger Bands 0.39
    Lower Bollinger Band 0.16
    Percent B (%b) 0.54
    BandWidth 83.68
    MACD Line -0.01
    MACD Signal Line -0.01
    MACD Histogram 0.0047
    Fundamentals Value
    Market Cap 12.4 Million
    Num Shares 43.3 Million
    EPS -1.10
    Price-to-Earnings (P/E) Ratio -0.26
    Price-to-Sales 0.00
    Price-to-Book 2.97
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.32
    Resistance 3 (R3) 0.32 0.31 0.31
    Resistance 2 (R2) 0.31 0.30 0.31 0.31
    Resistance 1 (R1) 0.30 0.29 0.30 0.30 0.31
    Pivot Point 0.28 0.28 0.29 0.28 0.28
    Support 1 (S1) 0.27 0.28 0.28 0.28 0.26
    Support 2 (S2) 0.26 0.27 0.26 0.26
    Support 3 (S3) 0.25 0.26 0.26
    Support 4 (S4) 0.25